Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1642, Issue 3, 2003, Pages 129-138

  Ishimoto, Yoshikazu ^a   Yamada, Katsutoshi ^a   Yamamoto, Shigenori ^a   Ono, Takashi ^a   Notoya, Mitsuru ^a   Hanasaki, Kohji ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Cholesterol efflux; Free fatty acid; High density lipoprotein; Lysophosphatidylcholine; Phospholipase A2

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 IB; SECRETORY PHOSPHOLIPASE A2 IIA; SECRETORY PHOSPHOLIPASE A2 V; SECRETORY PHOSPHOLIPASE A2 X; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; ATHEROGENESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; FATTY ACID SYNTHESIS; FOAM CELL; HYDROLYSIS; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; LIPID OXIDATION; LIPOLYSIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ORYCTOLAGUS CUNICULUS;

EID: 0142200309     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(03)00120-4     Document Type: Article

References (64)

1. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321:1989;1311-1316.
2. Eisenberg S. High density lipoprotein metabolism. J. Lipid Res. 25:1984;1017-1058.
3. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86:1990;379-384.
4. Yancey P.G., Llera-Moya M., Swarnakar S., Monzo P., Klein S.M., Connelly M.A., Johnson W.J., Williams D.L., Rothblat G.H. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275:2000;36596-36604.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
6. 2 in the pathobiology of disease. Lab. Invest. 55:1986;391-404.
7. 2: its generation and role in platelet activation. Prog. Lipid Res. 28:1989;273-301.
8. 2 enzymes: classification and characterization. Biochim. Biophys. Acta. 1488:2000;1-19.
9. 2. Trends Pharmacol. Sci. 20:1999;162-170.
10. 2s. J. Biol. Chem. 274:1999;24973-24979.
11. 2s. J. Biol. Chem. 275:2000;5785-5793.
12. 2. J. Biol. Chem. 275:2000;39823-39826.
13. Collet X., Perret B.P., Simard G., Vieu C., Douste-Blazy L. Behaviour of phospholipase-modified HDL towards cultured hepatocytes: I. Enhanced transfers of HDL sterols and apoproteins. Biochim. Biophys. Acta. 1043:1990;301-310.
14. 2 in human atherosclerotic plaques. Atherosclerosis. 118:1995;173-181.
15. 2. Arterioscler. Thromb. Vasc. Biol. 19:1999;1284-1290.
16. 2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry. 41:2002;4911-4920.
17. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem. 274:1999;34203-34211.
18. 2 induces potent productions of various lipid mediators in mouse peritoneal macrophages. Biochim. Biophys. Acta. 1530:2001;67-76.
19. 2 receptor. Arch. Biochem. Biophys. 381:2000;31-42.
20. 2 formation during colon tumorigenesis. FEBS Lett. 487:2000;262-266.
21. 2 is linked to macrophage foam cell formation. J. Biol. Chem. 277:2002;29116-29124.
22. Goldstein J.L., Kita T., Brown M.S. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N. Engl. J. Med. 309:1983;288-296.
23. 2: synthesis and inhibitory activities of indolizine and indene derivatives. J. Med. Chem. 39:1996;3636-3658.
24. Hara S., Shike T., Takasu N., Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;1258-1266.
25. 2 isozymes. J. Lipid Res. 34:1993;837-844.
26. Chalvardjian A., Rudnicki E. Determination of lipid phosphorus in the nanomolar range. Anal. Biochem. 36:1970;225-226.
27. Nagano Y., Arai H., Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. Natl. Acad. Sci. U. S. A. 88:1991;6457-6461.
28. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J. Lipid Res. 9:1968;693-700.
29. Tong H., Knapp H.R., VanRollins M. A low temperature flotation method to rapidly isolate lipoproteins from plasma. J. Lipid Res. 39:1998;1696-1704.
30. Gamble W., Vaughan M., Kruth H.S., Avigan J. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J. Lipid Res. 19:1978;1068-1070.
31. 2 protein and mRNA in rat tissues. J. Histochem. Cytochem. 48:2000;1469-1477.
32. 2 in the human gastrointestinal tract. Lab. Invest. 72:1995;201-208.
33. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
34. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85:1990;1234-1241.
35. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267.
36. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9607-9611.
37. Kume N., Gimbrone M.A. Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 93:1994;907-911.
38. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 85:1988;2805-2809.
39. Ji Y., Jian B., Wang N., Sun Y., Moya M.L., Phillips M.C., Rothblat G.H., Swaney J.B., Tall A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. 272:1997;20982-20985.
40. Jian B., Llera-Moya M., Royer L., Rothblat G., Francone O., Swaney J.B. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res. 38:1997;734-744.
41. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., Seilhamer J.J., Vaughan A.M., Oram J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104:1999;R25-R31.
42. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W.E., Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 257:1999;29-33.
43. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
44. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
45. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
46. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., Isaia P., Berg J., Janus E.D., Smith M.P. Jr., Pritchard P.H., Frohlich J., Lees R.S. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107:1994;85-98.
47. Wang Y., Oram J.F. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J. Biol. Chem. 277:2002;5692-5697.
48. Graham A., Hassall D.G., Rafique S., Owen J.S. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135:1997;193-204.
49. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
50. Banka C.L. High density lipoprotein and lipoprotein oxidation. Curr. Opin. Lipidol. 7:1996;139-142.
51. Desai K., Bruckdorfer K.R., Hutton R.A., Owen J.S. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J. Lipid Res. 30:1989;831-840.
52. Nofer J.R., Walter M., Kehrel B., Wierwille S., Tepel M., Seedorf U., Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide- derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 18:1998;861-869.
53. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., Seedorf U., Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276:2001;34480-34485.
54. Hevonoja T., Pentikainen M.O., Hyvonen M.T., Kovanen P.T., Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta. 1488:2000;189-210.
55. 2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17:1997;2257-2263.
56. 2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler. Thromb. Vasc. Biol. 18:1998;519-525.
57. 2 and decorin in human atherosclerotic lesions. Circ. Res. 86:2000;707-714.
58. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21:2001;1053-1058.
59. 2 in vascular disease. Circ. Res. 89:2001;298-304.
60. 2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J. Biol. Chem. 275:2000;10077-10084.
61. 2. J. Biol. Chem. 271:1996;32381-32384.
62. De Caterina R., Mazzone A., Giannessi D., Sicari R., Pelosi W., Lazzerini G., Azzara A., Forder R., Carey F., Caruso D.et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed. Biochim. Acta. 47:1988;S182-S185.
63. Cipollone F., Prontera C., Pini B., Marini M., Fazia M., De Cesare D., Iezzi A., Ucchino S., Boccoli G., Saba V., Chiarelli F., Cuccurullo F., Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation. 104:2001;921-927.
64. 2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem. 271:1996;32381-32384.